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ABSTRACT
Background. Little is known about the association
between signet ring cell (SRC) differentiation and response
to neoadjuvant chemotherapy (nCT) or neoadjuvant
chemoradiotherapy (nCRT) in patients with esophageal
and junctional adenocarcinoma (EAC). We aimed to assess
if SRC differentiation is associated with survival and
response to nCT or nCRT in patients with EAC.
Methods. Patients who underwent nCT and nCRT fol-
lowed by surgery for EAC from 2000 until 2016 were
identified from two institutional prospectively maintained
databases. The pretreatment biopsy report or surgical
resection specimen was used to differentiate patients into
an SRC or non-SRC group.
Results. Overall, 129 (19%) of 689 patients included had
SRCs (nCT: n = 64; nCRT: n = 65). The SRC group had a
more advanced ypT stage (p = 0.003), a higher number of
positive lymph nodes in the resection specimen {median
(interquartile range [IQR]) 2 [0–5] vs. 1 [0–3]; p = 0.002}
and a higher rate of R1/R2 resections (19.4% vs. 12%;
p = 0.026). SRC differentiation was not an independent
prognostic factor for overall survival (OS) or disease-free
survival (DFS). Following nCT, the SRC group had sig-
nificantly shorter DFS (median [IQR] 12 [5–50] vs. 23
[8–164]; p = 0.013), but not OS, compared with the non-
SRC group. In contrast, no differences according to SRC
status for OS or DFS were found in patients who underwent
nCRT.
Conclusions. SRC differentiation was not independently
associated with worse OS in patients with EAC who
underwent neoadjuvant therapy and surgery. However,
nCRT was associated with greater tumor downstaging and
better DFS.
At present, neoadjuvant chemotherapy (nCT) or
neoadjuvant chemoradiotherapy (nCRT) is indicated for
patients with resectable esophageal cancer, given the
improvement of survival in patients after multimodality
treatment. However, the survival benefit of neoadjuvant
treatment is limited to patients who respond to this treat-
ment as defined by pathological response evaluation.1 A
complete pathologic response is used as a prognostic
indicator for overall survival (OS); however, a recent study
questioned its validity as a surrogate endpoint for OS.2
Ideally, pretreatment genetic markers could serve as novel
predictors of response to preoperative therapy. As there has
been little progress in this field, histological subtyping
might serve as an alternative.
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Little is known about the effect of signet ring cell (SRC)
differentiation on response to nCT or nCRT and survival in
patients with esophageal and junctional adenocarcinoma
(EAC). The optimal neoadjuvant treatment strategy for
SRC tumors is therefore unknown. In patients with gastric
cancer, SRCs are associated with poor prognosis.3 Recent
studies have shown that response to nCT is poor in patients
with SRC gastric cancer, and the benefit of nCT in this type
of tumor is debated.4,5 SRC histology in patients with EAC
may also be used as a predictor of prognosis and response
to treatment. A pretreatment assessment of SRC differen-
tiation in tumor biopsies could help to select patients who
may or may not benefit from neoadjuvant treatment, and to
predict prognosis in patients. Moreover, multimodality
approaches are associated with a considerable rate of
adverse events6–8 and it would be of great help to be able to
better identify patients who benefit from preoperative
treatment.
The rate of response to nCT in EAC patients with SRC
tumors seems to be limited.5 However, Bekkar et al.9 found
that patients with locally advanced SRC adenocarcinoma
of the esophagus treated with chemoradiotherapy prior to
surgery have a better outcome compared with surgery
alone. Due to the local infiltrating character of SRC,
chemoradiotherapy could potentially have a positive effect
in these patients as adjunctive locoregional treatment prior
to surgery.4 In their study, Bleaney et al.10 concluded that
patients with adenocarcinomas with SRC differentiation
have a different response to neoadjuvant therapy than non-
SRC adenocarcinomas, but the exact impact of SRC dif-
ferentiation on neoadjuvant treatment and prognosis in
esophageal adenocarcinomas remains unclear. Therefore,
the aim of this study was to investigate the association of
SRC differentiation with response to neoadjuvant treatment
and survival in patients with EACs.
METHODS
Patients
A retrospective study was conducted using two
prospectively maintained databases of the Departments of
Surgery at the Erasmus University Medical Centre (Eras-
mus MC), Rotterdam, The Netherlands, and the Princess
Alexandra Hospital (PA Hospital), Brisbane, Australia. In
both institutions, ethical approval was obtained. All
patients who underwent nCT or nCRT followed by
esophagectomy with curative intent for tumors of the
gastroesophageal junction or esophagus from 2000 until
2016 were included. Patients needed to have completed at
least two cycles of chemotherapy and, if applicable,
received a minimum total radiation dose of 35 Gy. Patient
records were reviewed to obtain information when missing.
Pretreatment biopsy reports were used to assess the tumor
histology and to differentiate patients into an SRC or non-
SRC group. In some patients, pretreatment biopsy reports
were not available. In these cases, the surgical resection
specimen was used to determine whether the tumor showed
SRC differentiation or not. A tumor was classified as
having SRC differentiation when any SRC morphology
was seen in the histologically assessed tissue, independent
of the percentage. Complete pathological responders who
did not have a biopsy report available were excluded. The
non-SRC group served as a reference group.
Pretreatment Staging
All patients were staged by endoscopy and computed
tomography (CT) of the chest and abdomen. Endoscopic
ultrasonography was used in selected patients from the PA
Hospital to clarify tumor and nodal staging, whereas it was
routinely used in all Erasmus MC patients. In the PA
Hospital, fluorodeoxyglucose-positron emission tomogra-
phy (FDG-PET) scanning has been routinely performed
since 2008, and, in the Erasmus MC, FDG-PET scanning
was introduced in 2008 to obtain assurance of no further
distant dissemination when conventional imaging showed
signs of extensive lymph node involvement and became a
standard procedure in 2013.
Treatment
The nCRT regimen administered to all patients from the
Erasmus MC was as per the CROSS protocol.11 PA
Hospital patients mainly received a combination of two
cycles cisplatin and 5-fluoruracil administered with a total
radiation dose of either 35 Gy in 15 fractions or 45 Gy in
25 fractions, commencing the radiotherapy with the second
cycle of chemotherapy. A small number of these patients
were administered additional docetaxel. Since 2015, there
has been an increasing use of the CROSS regimen in PA
Hospital patients. The majority of the Erasmus MC nCT
patients was treated with either carboplatin or cisplatin, in
combination with paclitaxel. Other patients received peri-
operative chemotherapy consisting of a combination of
epirubicin, cisplatin and capecitabine, administered in three
cycles before surgery and three cycles after surgery. PA
Hospital patients receiving nCT were administered similar
chemotherapeutic regimens as their nCRT-treated patients,
most commonly as per the OEO2 protocol.12 However, a
moderate number of nCT patients were treated according to
the MAGIC protocol.13 The surgical technique used was
dependent on tumor location and local expertise or pref-
erences. Details of the surgical techniques in the PA
2376 S. J. M. van Hootegem et al.
Hospital and Erasmus MC have been previously
described.14,15
Pathological Assessment
All resection specimens were assessed by experienced
gastrointestinal (GI) pathologists to determine the patho-
logic tumor (ypT), nodal (ypN) and distant metastasis
(ypM) stage in accordance with the TNM staging system of
the Union for International Cancer Control/American Joint
Committee on Cancer (7th edition).16 Specimens with
tumor cells present within 1 mm of the resection margin
were considered to be an R1 resection.17 Tumor regression
was graded according to the Mandard score.18
Follow-Up and Recurrence
After esophagectomy, patients were seen every
3 months for the first 2 years. The following 3 years,
patients were assessed at 6-month intervals, and annually
up to 5 (Erasmus MC) or 10 years (PA Hospital). Follow-
up visits included patient’s history and physical examina-
tion. Symptoms suggestive of recurrence were investigated
using a CT scan and endoscopy if indicated. Further
investigations were performed on individual basis. Recur-
rence was documented by site of first recurrence, dividing
it into locoregional, distant, or both. Locoregional recur-
rence was defined as disease recurring within the previous
esophageal bed, at the anastomotic site, or as disease
recurring in the draining lymphatic basins, depending on
the prior tumor site. Distant recurrence was defined as any
lymphatic dissemination further than regional lymphatic
basins, as well as recurrence in any distant organ. Recur-
rence present in more than one anatomical location was
regarded as synchronous if detected within 4 weeks of
documented recurrence.
Statistical Analysis
Differences between groups were tested using Pearson’s
Chi square test or Fisher’s exact test for categorical data,
and Mann–Whitney U test for non-parametric continuous
data. Categorical variables were reported as numbers and
percentages, and distribution of continuous characteristics
was reported as median (interquartile range [IQR]) or
mean ± standard deviation (SD). OS was calculated as the
time between surgery and death by any cause or last fol-
low-up, while disease-free survival (DFS) was calculated
as the time between surgery and histologically proven or
radiological evidence of recurrence, or death by any cause.
Survival curves were obtained using the Kaplan–Meier
method, and differences were tested using the log-rank test.
Cox regression analysis was used to assess the relation of
clinical and pathological variables with OS and DFS.
Multiple multivariable models were composed to assess the
prognostic significance of SRC differentiation on OS and
DFS, separately for nCT and nCRT. A p value B 0.05
(two-sided) was considered to be statistically significant for
all data. All analysis was performed using SPSS version
25.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Patients
A total of 714 patients matched the inclusion criteria.
Twenty-five patients were excluded as detailed pathology
reports were missing. Of the remaining 689 study patients,
129 patients had tumors that showed SRC histology (nCT,
n = 64; nCRT, n = 65), and 560 patients had no evidence
of SRC (nCT, n = 234; nCRT, n = 326). A total of 93
(SRC, n = 10; non-SRC, n = 83) patients did not have a
biopsy report available and the resection specimen was
used to determine whether the tumor showed SRC histol-
ogy. Electronic supplementary Table 1 shows details
regarding neoadjuvant treatment.
No statistically significant differences in clinical char-
acteristics were found between the SRC and non-SRC
groups (Table 1); however, pathological T stage (ypT
stage) [p = 0.003], number of positive lymph nodes in the
resection specimen (median [IQR] 2 [0–5] vs. 1 [0–3];
p = 0.002) and proportion of R1/R2 resections (19.4% vs.
12.0%; p = 0.026) were higher in the SRC group (Table 2).
No significant difference was seen in response to therapy
according to the Mandard score, between the SRC and non-
SRC groups. A comparison between Erasmus MC and PA
Hospital patients is shown in electronic supplementary
Table 2.
The subgroup of patients with SRC tumors treated with
nCT had more advanced ypT stage (p = 0.004) and more
irradical resections (29.7% vs. 17.9; p = 0.039). There
were no statistically significant differences in pathological
characteristics between the SRC and non-SRC groups for
patients treated with nCRT (electronic supplementary
Table 3).
Overall Survival
Median OS time for the SRC group was 29 months (IQR
10–111), whereas non-SRC patients had a median OS of
41 months (IQR 14–not reached; p = 0.081) (Fig. 1a).
There was also no statistically significant difference in OS
according to SRC status following nCT (p = 0.076)
(Fig. 1b) or nCRT (p = 0.541) (Fig. 1c).
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In nCT patients, only advanced ypTNM stage, R1/R2
resection, and SRC status were associated with worse OS
in univariable analysis (Table 3). However, in multivari-
able analysis, SRC status was not an independent predictor
of OS, while resection margin remained a significant pre-
dictor. Univariable analysis in nCRT patients showed that
increased age, advanced ypTNM stage, Mandard score of
3–5, and an R1/R2 resection status were associated with
lower OS. In multivariable analysis, age and advanced
ypTNM stage were independent predictors of OS. SRC
status was not associated with worse OS, neither in uni-
variable nor multivariable analysis.
Disease-Free Survival
Median DFS for SRC and non-SRC patients was
21 months (IQR 6–111) and 29 months (IQR 9–164),
respectively (p = 0.081) (Fig. 1d). For patients who
underwent nCT, the SRC group had a median DFS of
12 months (IQR 5–50) compared with 23 months (IQR
8–164) for the non-SRC group (p = 0.013) (Fig. 1e). In
patients who underwent nCRT, median DFS was
26 months (IQR 10–111) in the SRC group, and 35 months
(IQR 10–158) in the non-SRC group (p = 0.914) (Fig. 1f).
nCT patients in the SRC group had worse locoregional
recurrence-free survival (RFS; p = 0.003) (Fig. 1g), but not
distant RFS (p = 0.185) (Fig. 1h). Multivariable analysis
TABLE 1 Clinical and tumor
characteristics according to the
presence of SRC
Variables SRC [n = 129] Non-SRC [n = 560] p value
Age, years (mean [SD]) 61.98 [8.44] 61.53 [9.07] 0.945
Sex
Male 117 (90.7) 500 (89.3) 0.636
Female 12 (9.3) 60 (10.7)
Tumor location
Upper esophagus – 2 (0.4) 0.596
Middle 4 (3.1) 30 (5.4)
Lower 70 (54.3) 309 (55.2)
GO junction 55 (42.6) 219 (39.1)
cT stage
T1 – 12 (2.1) 0.213
T2 30 (23.3) 146 (26.1)
T3 92 (71.3) 373 (66.6)
T4 3 (2.3) 21 (3.8)
Missing 4 (3.1) 8 (1.4)
cN stage
N0 60 (46.5) 253 (45.2) 0.373
N1 50 (38.8) 219 (39.1)
N2 10 (7.8) 68 (12.1)
N3 2 (1.6) 8 (1.4)
N? 1 (0.8) 1 (0.2)
Nx 2 (1.6) 4 (0.7)
Missing 4 (3.1) 7 (1.3)
cM stage
M0 107 (82.9) 475 (84.8) 0.503
M1 7 (5.4) 28 (5)
Mx 11 (8.5) 50 (8.9)
Missing 4 (3.1) 7 (1.3)
Neoadjuvant treatment
nCRT 65 (50.4) 326 (58.2) 0.106
nCT 64 (49.6) 234 (41.8)
Data are expressed as n (%) unless otherwise specified
SRC signet ring cell, SD standard deviation, GO gastroesophageal, nCRT neoadjuvant chemoradiotherapy,
nCT neoadjuvant chemotherapy
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showed that advanced ypN and ypM staging were inde-
pendent predictors of DFS in both nCRT and nCT patients
(Table 4). Among nCT patients, resection margin was also
a significant predictor of DFS, in contrast to SRC status,
which was not.
DISCUSSION
This study shows that in patients with EAC treated with
neoadjuvant therapy plus surgery, SRC differentiation was
not an independent predictor for OS or DFS. However, in
patients who underwent nCT, SRC differentiation was
associated with a higher rate of R1/R2 resections and worse
locoregional RFS. Multivariable analysis in nCT patients
showed that resection margin was an independent predictor
of both OS and DFS.
Other studies have shown that tumors with SRC dif-
ferentiation possess unique clinical features, but still little
is known about the optimal treatment strategy for these
tumors.10 Median survival of SRC patients was inferior to
non-SRC patients. However, current nCRT treatment
seems to lead to comparable outcomes in tumors that show
SRC differentiation compared with tumors that do not.
Until 2015, nCT was the standard preoperative therapy for
EAC patients treated in the PA Hospital, while the role of
radiotherapy is still debated.19 The results of this study
raise the question as to whether the same outcome applies
to SRC tumors.
With regard to nCT, it is possible that the higher number
of R1/R2 resections in the SRC group could be a result of
selection bias instead of more aggressive tumor behavior;
however, our data indicate that this difference is not seen in
patients treated with nCRT. In the present study, the
TABLE 2 Pathological
characteristics according to the
presence of SRC
Variable SRC [n = 129] Non-SRC [n = 560] p value
ypT stage
T0 8 (6.2) 6 (11.2) 0.003
Tis – 2 (0.4)
T1 10 (7.8) 110 (19.6)
T2 21 (16.3) 102 (18.2)
T3 87 (67.4) 266 (47.5)
T4 3 (2.3) 17 (3)
Missing – 1 (0.2)
ypN stage
N0 50 (38.8) 256 (45.7) 0.323
N1 37 (28.7) 168 (30)
N2 23 (17.8) 80 (14.3)
N3 19 (14.7) 55 (9.8)
Missing – 1 (0.2)
ypM stage
M0 117 (90.7) 535 (95.5) 0.126
M1 11 (8.5) 23 (4.1)
Mx 1 (0.8) 1 (0.2)
Missing – 1 (0.2)
Mandard
TRG 1–2 33 (25.6) 183 (32.7) 0.196
TRG 3–5 83 (64.3) 312 (55.7)
Missing 13 (10.1) 65 (11.6)
Resection margin
R0 104 (80.6) 493 (88) 0.026
R1/R2 25 (19.4) 67 (12)
Lymph node yield (median [IQR]) 20 [16–26] 20 [15–28] 0.655
Positive lymph nodes (median [IQR]) 2 [0–5] 1 [0–3] 0.002
Data are expressed as n (%) unless otherwise specified
Bold values indicate statistical significance (p\ 0.05; two-sided)
SRC signet ring cell, TRG tumor regression grade, IQR interquartile range
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percentage of radical (R0) resections after nCRT was
comparable with previously reported data by Bekkar et al.9
In line with their study, we found that nCRT can lead to
more favorable outcomes in SRC patients. In addition,
lower radical resection rates in SRC patients treated with
nCT were also reported in other recent literature,2,4 and
resection margin status was an independent prognostic
factor in nCT patients in our study. This underlines the
prognostic impact of positive resection margins.
Ideally, all SRC-positive biopsies would have been
reassessed by an experienced pathologist to differentiate
the tumors into C 50% and\ 50% SRC groups. Unfortu-
nately, this was not feasible due to the retrospective nature
of the study. The majority of preoperative biopsies were
performed in the referring hospitals before patients were
sent to the tertiary center for (surgical) treatment. The
resection specimens from the Rotterdam cohort were ana-
lyzed by two experienced GI pathologists, and the Brisbane
samples were analyzed by experienced GI pathologists
TABLE 3 Univariable and multivariable analysis of the effects of clinicopathological variables on OS
Variables nCT nCRT
n Univariable analysis Multivariable analysis n Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 298 0.997 (0.98–1.01) 0.71 391 1.02 (1.00–1.03) 0.06 1.02 (1.01–1.04) 0.004
Sex
Male 265 Reference 352 Reference Reference
Female 33 0.92 (0.57–1.48) 0.72 39 0.64 (0.39–1.07) 0.09 0.68 (0.41–1.14) 0.15
Tumor location
Upper/middle
esophagus
11 Reference 25 Reference
Lower 150 0.78 (0.38–1.61) 0.50 229 0.97 (0.58–1.63) 0.90
GO junction 137 0.73 (0.36–1.52) 0.41 137 0.83 (0.48–1.43) 0.51
ypT stage
T0 14 Reference Reference 56 Reference Reference
T1 46 0.60 (0.24–1.50) 0.27 0.53 (0.21–1.34) 0.18 74 1.73 (0.96–3.12) 0.07 1.74 (0.95–3.19) 0.08
T2 46 0.72 (0.29–1.79) 0.48 0.50 (0.20–1.26) 0.14 77 1.96 (1.10–3.49) 0.02 1.56 (0.84–2.91) 0.16
T3 177 1.57 (0.69–3.57) 0.29 0.61 (0.26–1.47) 0.27 176 3.13 (1.85–5.28) \ 0.001 2.19 (1.20–4.01) 0.01
T4 15 3.4 (1.28–9.01) 0.01 1.09 (0.39–3.10) 0.87 5 8.47 (2.80–25.60) \ 0.001 5.46 (1.51–19.71) 0.01
ypN stage
N0 94 Reference Reference 212 Reference Reference
N1 95 2.75 (1.82–4.17) \ 0.001 2.48 (1.62–3.79) \ 0.001 120 2.13 (1.56–2.91) \ 0.001 2.12 (1.51–3.00) \ 0.001
N2 62 4.08 (2.61–6.37) \ 0.001 4.18 (2.59–6.75) \ 0.001 41 3.49 (2.33–5.25) \ 0.001 2.96 (1.86–4.72) \ 0.001
N3 47 5.94 (3.72–9.48) \ 0.001 5.17 (3.11–8.60) \ 0.001 27 4.52 (2.87–7.11) \ 0.001 3.70 (2.23–6.15) \ 0.001
ypM stage
M0 277 Reference Reference 375 Reference Reference
M1 21 4.16 (2.59–6.68) \ 0.001 4.04 (2.42–6.73) \ 0.001 13 3.46 (1.92–6.23) \ 0.001 3.13 (1.65–5.92) \ 0.001
Mandard
TRG 1–2 35 Reference 181 Reference Reference
TRG 3–5 232 0.56 (0.21–1.52) 0.26 198 1.61 (1.23–2.12) 0.001 0.85 (0.61–1.19) 0.34
Resection margin
R0 247 Reference Reference 360 Reference Reference
R1/R2 61 3.09 (2.23–4.27) \ 0.001 1.93 (1.34–2.79) \ 0.001 31 1.84 (1.18–2.86) 0.007 1.04 (0.62–1.73) 0.77
SRC status
Non-SRC 234 Reference Reference 326 Reference Reference
SRC 64 1.36 (0.97–1.90) 0.08 1.08 (0.76–1.54) 0.66 65 1.12 (0.79–1.58) 0.54 0.86 (0.59–1.24) 0.41
Variables were entered in the multivariable model if the p value was\ 0.1 in the univariable analysis
The Mx (n = 2) and Tis (n = 2) categories were not included in the analysis
nCRT neoadjuvant chemoradiotherapy nCT neoadjuvant chemotherapy, HR hazard ratio, CI confidence interval, GO gastroesophageal, TRG tumor
regression grade, SRC signet ring cell, OS overall survival
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working at either the PA Hospital or one of two large
private pathology practices. While blinded, central
pathology review of all cases would be ideal, this was not
possible for the present study as many patients’ tissue
blocks or slides were unavailable. Clarification of the
amount of SRC found in the biopsied tissue is said to be
A B
C D
E F
FIG. 1 Survival curves according to SRC status. a Overall survival;
p = 0.081; b overall survival in the nCT group; p = 0.076; c overall
survival in the nCRT group; p = 0.541; d disease-free survival;
p = 0.081; e disease-free survival in the nCT group; p = 0.013;
f disease-free survival in the nCRT group; p = 0.914; g locoregional
recurrence-free survival in the nCT group; p = 0.003; h distant
recurrence-free survival in the nCT group; p = 0.185. SRC signet
ring cell, nCRT neoadjuvant chemoradiotherapy, nCT neoadjuvant
chemotherapy
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FIG. 1 continued
TABLE 4 Univariable and multivariable analysis of effects of clinicopathological variables on DFS
Variables nCT nCRT
n Univariable analysis Multivariable analysis n Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 298 1.00 (0.98–1.02) 0.91 391 1.01 (1.00–1.03) 0.11
Sex
Male 265 Reference 352 Reference
Female 33 0.92 (0.59–1.46) 0.73 39 0.74 (0.46–1.20) 0.22
Tumor location
Upper/middle esophagus 11 Reference 25 Reference
Lower 150 0.90 (0.44–1.84) 0.76 229 1.00 (0.59–1.68) 0.99
GO junction 137 0.86 (0.42–.78) 0.69 137 0.90 (0.52–1.56) 0.71
ypT stage
T0 14 Reference Reference 56 Reference Reference
T1 46 0.74 (0.30–1.83) 0.51 0.66 (0.26–1.65) 0.37 74 1.74 (0.98–3.09) 0.06 1.77 (0.98–3.20) 0.06
T2 46 0.85 (0.34–2.10) 0.72 0.57 (0.22–1.65) 0.23 77 1.97 (1.12–3.45) 0.02 1.52 (0.83–2.77) 0.18
T3 177 1.73 (0.76–3.95) 0.19 0.60 (0.25–1.44) 0.25 176 3.00 (1.80–5.00) \ 0.001 2.15 (1.19–3.90) 0.01
T4 15 3.52 (1.33–9.32) 0.01 1.12 (0.395–3.18) 0.83 5 6.36 (2.13–19.05) 0.001 4.19 (1.19–14.68) 0.03
ypN stage
N0 94 Reference Reference 212 Reference Reference
N1 95 2.85 (1.90–4.30) \ 0.001 2.59 (1.70–3.95) \ 0.001 120 2.40 (1.77–3.26) \ 0.001 2.36 (1.69–3.31) \ 0.001
N2 62 4.71 (3.06–7.26) \ 0.001 4.98 (3.11–8.00) \ 0.001 41 3.13 (2.06–4.76) \ 0.001 2.57 (1.61–4.10) \ 0.001
N3 47 5.88 (3.72–9.29) \ 0.001 5.42 (3.29–8.94) \ 0.001 27 4.35 (2.71–6.99) \ 0.001 3.27 (1.92–5.57) \ 0.001
ypM stage
M0 277 Reference Reference 375 Reference Reference
M1 21 5.10 (3.20–8.14) \ 0.001 5.48 (3.32–9.04) \ 0.001 13 4.16 (2.36–7.33) \ 0.001 4.30 (2.26–8.18) \ 0.001
Mandard
TRG 1–2 35 Reference 181 Reference Reference
TRG 3–5 232 0.61 (0.23–1.65) 0.33 198 2.28 (1.34–3.88) 0.002 0.85 (0.60–1.19) 0.33
Resection margin
R0 247 Reference Reference 360 Reference Reference
R1/R2 61 3.01 (2.18–4.14) \ 0.001 1.97 (1.38–2.81) \ 0.001 31 1.73 (1.10–2.72) 0.02 0.96 (0.56–1.63) 0.87
SRC status
Non-SRC 234 Reference Reference 326 Reference Reference
SRC 64 1.50 (1.08–2.07) 0.02 1.27 (0.90–1.78) 0.17 65 0.98 (0.68–1.41) 0.92 0.76 (0.51–1.12) 0.17
Variables were entered in the multivariable model if the p value was\ 0.1 in the univariable analysis
The Mx (n = 2) and Tis (n = 2) categories were not included in the analysis
nCRT neoadjuvant chemoradiotherapy, nCT neoadjuvant chemotherapy, HR hazard ratio, CI confidence interval, GO gastroesophageal, TRG tumor regression grade, SRC
signet ring cell, DFS disease-free survival
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inaccurate to determine whether the tumor truly consists of
50% SRC or more.20 In addition, Patel et al.21 reported that
mixed subtypes of adenocarcinoma, i.e. tumors consisting
of a non-SRC component admixed with an SRC compo-
nent, have inferior survival outcomes. In their study, SRC
histology was a significant predictor of survival and thus
they suggested that even a small percentage of SRCs can
have a clinical impact on tumor behavior. This finding
partly concurs with our study as we also found inferior
survival times in the SRC group, although this did not
reach statistical significance.
A limitation of this study is its retrospective nature, with
inclusion of patients treated over an extended period of
time, resulting in bias as a consequence of evolving treat-
ment practices. However, selecting patients from two
different centers limits the effect of possible selection bias
and treatment habits. Furthermore, a variety of platinum-
based regimens has been used due to the diverse standard
treatments in both institutions. However, the vast majority
of patients were treated with well-known and widely
applied regimens according to the CROSS,11 MAGIC,13
and OEO2 trials.12 Finally, the resection specimens were
analyzed by different pathologists, which might have
affected uniformity in the assessment of response to ther-
apy. To minimize the impact of possible interobserver
variability, we grouped the Mandard scores into responder
(tumor regression grade [TRG] 1–2) and non-responder
(TRG 3–5) groups.
CONCLUSIONS
SRC differentiation is not an independent predictor of
OS or DFS in patients who underwent neoadjuvant therapy
followed by surgery; however, SRC tumors may respond
differently according to the type of neoadjuvant treatment.
In nCT patients, the SRC group had more R1/R2 resec-
tions, which in turn was associated with worse locoregional
RFS. Hence, it is possible that nCRT provides additional
benefit in SRC patients as it could offer better locoregional
control. Further study of the efficacy of locoregional
therapy intensification would therefore seem warranted.
Although this study brings nuance to the question as to
what the impact is of SRC on neoadjuvant treatment,
determining an optimal treatment strategy for EAC SRC
tumors would require a multicenter cohort study comparing
nCRT and nCT more directly.
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